Laurus Labs Ltd
Laurus Labs is principally engaged in offering a broad and integrated portfolio of Active Pharmaceuticals Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry.
- Market Cap ₹ 18,037 Cr.
- Current Price ₹ 335
- High / Low ₹ 606 / 279
- Stock P/E 23.7
- Book Value ₹ 75.3
- Dividend Yield 0.60 %
- ROCE 22.1 %
- ROE 20.4 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 34.4% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.3%
Cons
- Promoter holding has decreased over last 3 years: -4.84%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
451 | 719 | 1,160 | 1,326 | 1,775 | 1,892 | 2,027 | 2,236 | 2,797 | 4,769 | 4,707 | 5,773 | |
373 | 573 | 951 | 1,121 | 1,402 | 1,478 | 1,618 | 1,884 | 2,226 | 3,258 | 3,421 | 4,292 | |
Operating Profit | 78 | 145 | 209 | 205 | 372 | 414 | 409 | 352 | 571 | 1,511 | 1,286 | 1,482 |
OPM % | 17% | 20% | 18% | 15% | 21% | 22% | 20% | 16% | 20% | 32% | 27% | 26% |
1 | 5 | 9 | 34 | 4 | 32 | 28 | 15 | 5 | 26 | 20 | 16 | |
Interest | 40 | 41 | 64 | 106 | 111 | 97 | 75 | 86 | 88 | 66 | 96 | 146 |
Depreciation | 18 | 23 | 33 | 61 | 86 | 104 | 121 | 161 | 184 | 197 | 235 | 301 |
Profit before tax | 22 | 86 | 121 | 72 | 180 | 245 | 241 | 121 | 304 | 1,275 | 975 | 1,051 |
Tax % | 0% | -2% | 20% | -2% | 19% | 18% | 28% | 22% | 12% | 25% | 23% | 28% |
Net Profit | 22 | 88 | 97 | 74 | 145 | 200 | 173 | 95 | 267 | 956 | 750 | 760 |
EPS in Rs | 2.83 | 11.58 | 12.64 | 9.47 | 18.36 | 3.78 | 3.27 | 1.78 | 5.00 | 17.82 | 13.96 | 14.12 |
Dividend Payout % | 0% | 0% | 0% | 0% | 2% | 8% | 9% | 17% | 10% | 11% | 14% | 14% |
Compounded Sales Growth | |
---|---|
10 Years: | 23% |
5 Years: | 23% |
3 Years: | 27% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | 24% |
5 Years: | 34% |
3 Years: | 42% |
TTM: | 1% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 29% |
3 Years: | 54% |
1 Year: | -41% |
Return on Equity | |
---|---|
10 Years: | 21% |
5 Years: | 23% |
3 Years: | 27% |
Last Year: | 20% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
78 | 78 | 78 | 82 | 82 | 106 | 106 | 106 | 107 | 107 | 107 | 108 | |
Reserves | 91 | 182 | 281 | 645 | 790 | 1,250 | 1,407 | 1,484 | 1,709 | 2,605 | 3,281 | 3,949 |
225 | 292 | 543 | 821 | 1,015 | 808 | 947 | 1,009 | 1,051 | 1,411 | 1,653 | 1,714 | |
181 | 212 | 434 | 411 | 409 | 509 | 547 | 718 | 872 | 1,502 | 1,567 | 1,187 | |
Total Liabilities | 513 | 701 | 1,273 | 1,893 | 2,229 | 2,673 | 3,008 | 3,318 | 3,739 | 5,625 | 6,609 | 6,958 |
187 | 236 | 499 | 801 | 1,014 | 1,193 | 1,448 | 1,599 | 1,694 | 1,818 | 2,186 | 2,884 | |
CWIP | 32 | 73 | 116 | 107 | 70 | 143 | 163 | 107 | 67 | 324 | 755 | 357 |
Investments | 0 | 0 | 0 | 19 | 26 | 51 | 52 | 58 | 58 | 319 | 362 | 384 |
294 | 393 | 658 | 966 | 1,119 | 1,286 | 1,345 | 1,554 | 1,920 | 3,164 | 3,306 | 3,333 | |
Total Assets | 513 | 701 | 1,273 | 1,893 | 2,229 | 2,673 | 3,008 | 3,318 | 3,739 | 5,625 | 6,609 | 6,958 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
39 | 88 | 121 | -59 | 197 | 321 | 369 | 293 | 345 | 694 | 823 | 882 | |
-46 | -124 | -312 | -406 | -315 | -282 | -417 | -257 | -217 | -900 | -837 | -735 | |
11 | 34 | 203 | 486 | 90 | -47 | 49 | -37 | -127 | 243 | 15 | -185 | |
Net Cash Flow | 4 | -2 | 12 | 21 | -27 | -8 | 0 | -0 | 0 | 38 | 2 | -39 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 120 | 80 | 61 | 78 | 91 | 108 | 100 | 112 | 102 | 98 | 98 | 94 |
Inventory Days | 136 | 138 | 165 | 210 | 177 | 184 | 199 | 201 | 233 | 257 | 279 | 211 |
Days Payable | 133 | 117 | 114 | 101 | 91 | 110 | 106 | 144 | 157 | 194 | 140 | 90 |
Cash Conversion Cycle | 123 | 101 | 112 | 187 | 177 | 183 | 193 | 169 | 177 | 161 | 237 | 216 |
Working Capital Days | 120 | 93 | 48 | 119 | 117 | 126 | 124 | 116 | 119 | 127 | 140 | 138 |
ROCE % | 17% | 27% | 25% | 15% | 17% | 17% | 14% | 8% | 14% | 38% | 23% | 22% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
24 May - Annual secretarial compliance report required under Regulation 24A of the SEBI (LODR) Regulations, 2015, issued by the Practicing Company Secretary for the year ended March …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
20 May - 'Regulations'), the details of Analyst/Institutional Investor meeting scheduled on May 24, 2023.
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 9 May
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
3 May - With reference to our Results conference call intimation dated April 21, 2023, please be informed that the Results conference call for Full year and Q4 …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2 May - It has received the USFDA tentative approval of the World''s First Oral Dispersible Film (ODF) Dolutegravir 5mg and 10mg for Pediatric ARV treatment. This innovative …
Annual reports
Concalls
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Mar 2022Transcript PPT
-
Jan 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
May 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
May 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Jan 2018Transcript PPT
-
Nov 2017Transcript PPT
-
Aug 2017TranscriptNotesPPT
-
May 2017Transcript PPT
-
Feb 2017TranscriptPPT
Integrated Pharma Company[1] Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in Active Pharmaceutical Ingredients (APIs) in selected high-growth therapeutic areas and a major focus on anti-retroviral, Hepatitis C, and oncology drugs.